Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- ASKA: Higher Cost Ratio Results in Profit Slump
May 29, 2006
- GENERIC NEWS IN BRIEF
May 29, 2006
- Mr Nogimori Wants to Make
May 22, 2006
- REGULATORY NEWS IN BRIEF
May 22, 2006
- SURVEY 3 articles
May 22, 2006
- NEW PRODUCTS
May 22, 2006
- Tanabe Seiyaku Announces
May 22, 2006
- Eisai Starts PI Trial for
May 22, 2006
- Daiichi Sankyo: Olmesartan
May 22, 2006
- CPHI JAPAN 2006
May 22, 2006
- DSP to See Combined Sales of
May 22, 2006
- R&D NEWS IN BRIEF
May 22, 2006
- MPC Predicts 3rd-Straight Year of Record Profits
May 22, 2006
- Projections of Med. Expenditure
May 22, 2006
- Teijin: Medical/Pharmaceutical
May 22, 2006
- Novartis to Launch
May 22, 2006
- Asahi Kasei Pharma: Profits
May 22, 2006
- Approval of New Type Influenza
May 22, 2006
- Kaken Licenses Antifungal KP-103 to Dow
May 22, 2006
- MEDICAL DEVICE NEWS IN BRIEF
May 22, 2006
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…